Xeris Pharmaceuticals begins Phase 2 trial for glucagon in Type 1 diabetes patients

pharmanewsdaily- March 31, 2019 0

Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to ... Read More

Biohaven secures orphan drug status for verdiperstat in MSA treatment

pharmanewsdaily- February 20, 2019 0

Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple ... Read More

Novus Therapeutics begins phase 1 trial of OP0201 in otitis media

pharmanewsdaily- February 11, 2019 0

Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The ... Read More

Pulmazole phase 2 clinical study gets FDA approval for Pulmazole in allergic bronchopulmonary aspergillosis

pharmanewsdaily- February 10, 2019 0

Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Pulmazole ... Read More

Prana Biotechnology secures FDA orphan drug status for PBT434 to treat multiple system atrophy

pharmanewsdaily- January 31, 2019 0

In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at ... Read More

Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma

pharmanewsdaily- November 4, 2018 0

Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of ... Read More

Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer

pharmanewsdaily- September 13, 2018 0

Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, ... Read More

Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors

pharmanewsdaily- July 15, 2018 0

Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More

Bayer and Janssen’s Xarelto shows promising results in reducing blood clot recurrence

pharmanewsdaily- March 19, 2017 0

Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN CHOICE clinical trial, showcasing the effectiveness of ... Read More

Symic Bio initiates SB-030 Phase 1/2a study in peripheral artery disease

pharmanewsdaily- February 25, 2017 0

Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase 1/2a clinical study, dubbed SHIELD, for its ... Read More

12320 / 22 Posts